(Total Views: 586)
Posted On: 06/11/2024 4:47:50 PM
Post# of 155870
.jpg)
Taken from the article. This is quite the UNendorsement.....YIKES. What is the FDA doing approving this drug that neurologists don't want to use??
NJ
Meanwhile, Dr. Clifford Segil, DO, a neurologist at Providence Saint John’s Health Center in Santa Monica, CA, told Medical News Today that he hopes the FDA committee will ultimately not approve donanemab, citing the experimental drug’s risks.
“I am hoping this is the beginning of the end to having anti-amyloid medications FDA-approved for the treatment of Alzheimer’s dementia. Clinical neurologists continue to not use this family of medications as they have not significantly improved patients’ memory loss in the drug trials and have caused severe cerebral edema and intracranial bleeding,” Dr. Segil said.
“There is no data it makes patients with Alzheimer’s dementia have any significant improvement in their cognitive complaints,” he added.
NJ
Meanwhile, Dr. Clifford Segil, DO, a neurologist at Providence Saint John’s Health Center in Santa Monica, CA, told Medical News Today that he hopes the FDA committee will ultimately not approve donanemab, citing the experimental drug’s risks.
“I am hoping this is the beginning of the end to having anti-amyloid medications FDA-approved for the treatment of Alzheimer’s dementia. Clinical neurologists continue to not use this family of medications as they have not significantly improved patients’ memory loss in the drug trials and have caused severe cerebral edema and intracranial bleeding,” Dr. Segil said.
“There is no data it makes patients with Alzheimer’s dementia have any significant improvement in their cognitive complaints,” he added.
(12)
(0)
